Cargando…

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

OBJECTIVE: Heart failure (HF) is an impactful complication of type 2 diabetes mellitus (T2DM). We aimed to develop and validate a risk score for hospitalization for HF (HHF) incorporating biomarkers and clinical factor(s) in patients with T2DM. RESEARCH DESIGN AND METHODS: We derived a risk score fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berg, David D., Wiviott, Stephen D., Scirica, Benjamin M., Zelniker, Thomas A., Goodrich, Erica L., Jarolim, Petr, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Braunwald, Eugene, Sabatine, Marc S., Morrow, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546278/ https://www.ncbi.nlm.nih.gov/pubmed/34535469 http://dx.doi.org/10.2337/dc21-1170

Ejemplares similares

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
por: Moura, Filipe A., et al.
Publicado: (2023)

Biomarker of Collagen Turnover (C‐Terminal Telopeptide) and Prognosis in Patients With Non‐ST‐Elevation Acute Coronary Syndromes
por: Zelniker, Thomas A., et al.
Publicado: (2019)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Early Insulinization to Prevent Diabetes Progression
por: Raz, Itamar, et al.
Publicado: (2013)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
por: Berg, David D., et al.
Publicado: (2021)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes
por: Kochba, Efrat, et al.
Publicado: (2016)

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
por: Røysland, Ragnhild, et al.
Publicado: (2012)

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2022)

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2023)

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
por: Zelniker, Thomas A, et al.
Publicado: (2019)

Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam
por: Khanh, Tran Quang, et al.
Publicado: (2020)

Prevention of cardiovascular disease guided by total risk estimations − challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy
por: Zannad, Faiez, et al.
Publicado: (2012)

When to start paediatric testing of the adult HIV cure research agenda?
por: Shah, Seema K
Publicado: (2017)

Risk and radical uncertainty in HIV research
por: Hare, Caspar
Publicado: (2017)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
por: Dagogo-Jack, Samuel, et al.
Publicado: (2021)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
por: Fanola, Christina L., et al.
Publicado: (2017)

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
por: Kato, Eri Toda, et al.
Publicado: (2022)

Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists
por: Cahn, Avivit, et al.
Publicado: (2015)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
por: Schechter, Meir, et al.
Publicado: (2020)

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach
por: Schechter, Meir, et al.
Publicado: (2022)

Lower Use of Hospice by Cancer Patients who Live in Minority Versus White Areas
por: Haas, Jennifer S., et al.
Publicado: (2007)

Accounting for failure: risk-based regulation and the problems of ensuring healthcare quality in the NHS
por: Beaussier, Anne-Laure, et al.
Publicado: (2016)

Diabetes and Stroke: What Are the Connections?
por: Mosenzon, Ofri, et al.
Publicado: (2023)

Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies
por: Leon, David A., et al.
Publicado: (2013)

Gene–obesogenic environment interactions in the UK Biobank study
por: Tyrrell, Jessica, et al.
Publicado: (2017)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Perceived Discrimination and Adherence to Medical Care in a Racially Integrated Community
por: Casagrande, Sarah Stark, et al.
Publicado: (2007)

Cardiac events within one year after a subarachnoid haemorrhage: The predictive value of troponin elevation after aneurysm occlusion
por: Akkermans, Annemarie, et al.
Publicado: (2018)

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
por: Cahn, Avivit, et al.
Publicado: (2016)

Effect of substance use on premature mortality among severely hypertensive African Americans
por: Varadarajan, Vinithra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2tsulig04usmfjjovgjnfl3r9u